KRAS Vaccine Safe and Immunogenic in Pancreatic Trial

An experimental vaccine designed to prevent pancreatic cancer in high-risk individuals has shown promising early results in a first-in-human clinical trial, generating durable immune responses and preventing cancer development in all participants during the study period. The findings, published on July 16, 2026, in the journal Cancer Discovery, represent a significant step toward a potential interception strategy for a notoriously lethal disease.

The phase 1 trial, conducted by researchers at the Johns Hopkins Kimmel Cancer Center, tested a vaccine called mKRASVAX in 20 adults at elevated hereditary risk for pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. All participants had radiographic evidence of pancreatic abnormalities, such as cysts. The vaccine is an off-the-shelf, synthetic formulation that targets six common mutations in the KRAS gene, a key driver present in roughly 90 percent of pancreatic cancers and many precancerous lesions.

Administered via subcutaneous injections over 13 weeks, the vaccine was found to be safe, with no severe adverse events reported. The most common side effects were mild to moderate, including injection-site...